NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

NextCure, Inc. (NASDAQ:NXTC) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 839,700 shares, an increase of 579.9% from the February 29th total of 123,500 shares. Based on an average daily trading volume, of 229,500 shares, the days-to-cover ratio is currently 3.7 days. Approximately 4.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NXTC. HC Wainwright increased their target price on NextCure from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Needham & Company LLC restated a “buy” rating and set a $4.00 price target on shares of NextCure in a report on Wednesday, March 20th.

NextCure Price Performance

Shares of NASDAQ:NXTC traded up $0.30 during trading on Thursday, hitting $2.23. The company had a trading volume of 1,014,865 shares, compared to its average volume of 254,665. The stock has a market cap of $62.22 million, a price-to-earnings ratio of -0.93 and a beta of 0.37. NextCure has a one year low of $0.98 and a one year high of $2.28. The company has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.31.

Institutional Investors Weigh In On NextCure

Institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in NextCure during the 4th quarter worth $30,000. Cable Car Capital LLC purchased a new position in shares of NextCure in the 4th quarter valued at $702,000. ADAR1 Capital Management LLC purchased a new position in shares of NextCure in the 4th quarter valued at $69,000. Marquette Asset Management LLC purchased a new position in shares of NextCure in the 4th quarter valued at $66,000. Finally, Acuitas Investments LLC grew its stake in NextCure by 30.0% during the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after buying an additional 85,982 shares during the last quarter. 42.65% of the stock is owned by institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.